By broadening definition of success to include sustained low-level HBsAg with suppressed HBV DNA, we can recognize clinically ...

GlobalData forecasts the hepatitis B therapeutics market will more than double to $3.2B by 2034, driven by functional cure drugs despite pricing and generic challenges.

The AUSHINE study is a randomized, double-blind, multicenter Phase III trial evaluating the efficacy and safety of AHB-137 injection in participants with HBeAg-negative CHB treated with nucleos (t)ide ...

Liver specialist Maurizio Bonacini is in the race for a cure for hepatitis B, one of the world’s most widespread diseases and a top cause of liver cancer around the globe. “It’s the last frontier,” ...

Hepatitis B virus infection remains one of the leading causes of liver disease, including cirrhosis and hepatocellular carcinoma. Despite widespread vaccination and antiviral treatments, millions of ...

A large percentage of US patients eligible for HBV treatment remain untreated, despite effective therapies reducing adverse outcomes like cirrhosis and hepatocellular carcinoma. Disparities in HBV ...

In their effort to answer a decades-old biological question about how the hepatitis B virus (HBV) is able to establish infection of liver cells, research led by Memorial Sloan Kettering Cancer Center ...

St. Louis -- In a pair of articles published in Lancet Gastroenterology and Hepatology, scientists lay out the case for why we should expand treatment recommendations for people with hepatitis B.

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A gene editing company in Durham ...

Medical experts have warned Nigerians against relying on herbal remedies to treat hepatitis, stressing that local concoctions cannot cure the viral liver disease.According to them, using herbal ...